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c-Ski is a transcriptional corepressor that interacts strongly with Smad2, Smad3, and Smad4 but only weakly with Smad1
and Smad5. Through binding to Smad proteins, c-Ski suppresses signaling of transforming growth factor- (TGF-) as
well as bone morphogenetic proteins (BMPs). In the present study, we found that a mutant of c-Ski, termed c-Ski (ARPG)
inhibited TGF-/activin signaling but not BMP signaling. Selectivity was confirmed in luciferase reporter assays and by
determination of cellular responses in mammalian cells (BMP-induced osteoblastic differentiation of C2C12 cells and
TGF-–induced epithelial-to-mesenchymal transdifferentiation of NMuMG cells) and Xenopus embryos. The ARPG
mutant recruited histone deacetylases 1 (HDAC1) to the Smad3-Smad4 complex but not to the Smad1/5-Smad4 complex.
c-Ski (ARPG) was unable to interact with Smad4, and the selective loss of suppression of BMP signaling by c-Ski (ARPG)
was attributed to the lack of Smad4 binding. We also found that c-Ski interacted with Smad3 or Smad4 without disrupting
Smad3-Smad4 heteromer formation. c-Ski (ARPG) would be useful for selectively suppressing TGF-/activin signaling.
INTRODUCTION
Cytokines of the transforming growth factor- (TGF-) su-
perfamily are multifunctional proteins that regulate growth,
differentiation, apoptosis, and morphogenesis of a wide va-
riety of cell types. TGF- and related factors bind to two
different types of serine/threonine kinase receptors, termed
type I and type II (Derynck et al., 1998; Attisano and Wrana,
2000; Shi and Massague´, 2003). Type I receptor is activated
by type II receptor upon ligand binding and transduces
signals into cytoplasm through phosphorylation of receptor-
regulated Smads (R-Smads). Phosphorylated R-Smads inter-
act with Co-Smad (Smad4) and translocate into the nucleus.
Nuclear Smad complexes regulate transcription of target
genes in cooperation with transcriptional activators/repres-
sors as well as with coactivators/corepressors (Miyazawa et
al., 2002). Of the eight different mammalian Smad proteins,
Smad1, Smad5, and Smad8 are R-Smads activated by BMP
family members, whereas Smad2 and Smad3 are R-Smads
activated by TGF- and activin.
Transcription of target genes by TGF- is upregulated by
binding of Smads to transcriptional coactivators, including
p300 and CBP, which induce acetylation of histones and
loosen chromatin structure (Massague´ and Chen, 2000;
Miyazono et al., 2001). In contrast, transcriptional corepres-
sors, including TGIF, c-Ski, and SnoN, physically interact
with Smads, and repress TGF- signaling through recruit-
ment of histone deacetylases (HDACs) (Massague´ and Chen,
2000; Liu et al., 2001).
c-Ski was originally identified as a cellular counterpart of
a retroviral oncogene product, v-Ski (Li et al., 1986). c-Ski
physically interacts with Smad2, Smad3, and Smad4, thus
antagonizing signal transduction in the TGF- pathway
(Akiyoshi et al., 1999; Luo et al., 1999; Sun et al., 1999; Xu et
al., 2000). Overexpression of c-Ski abolished TGF-–induced
growth inhibition (Luo et al., 1999; Sun et al., 1999; Xu et al.,
2000). High levels of expression of c-Ski were reported in
several tumor cell lines (Nomura et al., 1989; Fumagalli et al.,
1993) and in melanomas in vivo (Reed et al., 2001). Inhibition
of TGF- signaling is thus regarded as a part of the mecha-
nism of oncogenesis by Ski proteins (He et al., 2003). c-Ski
recruits HDACs via N-CoR as well as mSin3A and represses
transcriptional activities of Smads. In addition, c-Ski has
been shown to compete with p300 for binding to Smad3,
which may also play an important role in transcriptional
repression by c-Ski (Akiyoshi et al., 1999). Recently, a novel
model of the interaction of c-Ski with Smad-complexes was
proposed (Wu et al., 2002). In the model, c-Ski binds to L3
loop of Smad4, a loop that is responsible for interaction with
R-Smads; thus, c-Ski inhibits formation of active Smad com-
plex between R-Smads and Co-Smad. Although BMP-spe-
cific R-Smads bind to c-Ski only weakly (Akiyoshi et al.,
1999; Mizuide et al., 2003), it has been shown that c-Ski
inhibits BMP signaling in mammals and in Xenopus (Ama-
ravadi et al., 1997; Wang et al., 2000).
The ARPG mutant of Ski protein was first described in
v-Ski as a transformation-defective mutant (Colmenares et
al., 1991). The ARPG mutation is an insertional mutation of
four amino acids (Ala-Arg-Pro-Gly), replacing Asp in a po-
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tential amphipathic helix region (residue 181 in c-Ski and
residue 145 in v-Ski), which is supposed to disrupt helix
structure. v-Ski–infected cells exhibit morphological trans-
formation, anchorage-independent growth, and increased
growth rate, whereas v-Ski (ARPG)-infected cells do not.
v-Ski induces muscle differentiation in quail embryo cells as
judged by induction of MyoD, myogenin, and myotube
formation (Colmenares and Stavnezer, 1989), whereas v-Ski
(ARPG) induced only myotube formation (Colmenares et al.,
1991). v-Ski (ARPG) thus appeared to have signal-regulating
characteristics different from those of c-Ski and v-Ski. Sub-
sequently, Nomura et al. (1999) found that ARPG mutation
causes loss of interaction with NCoR.
In the present study, we found that c-Ski (ARPG) selec-
tively loses inhibitory activity on BMP signaling. Selectivity
of inhibition was confirmed in luciferase reporter assays and
by determination of cellular responses in mammalian cells
and Xenopus embryos. We also found that c-Ski (ARPG)
recruited HDAC1 to the Smad3-Smad4 complex, but not to
the Smad1/5-Smad4 complex, explaining the observed se-
lectivity. The difference in recruitment of HDAC1 to the two
types of Smad complexes was attributed to loss of Smad4
binding by c-Ski (ARPG). In addition, we examined the
effect of c-Ski on Smad3-Smad4 heteromer formation and
found that c-Ski can interact with Smad3 or Smad4 without
disrupting Smad3-Smad4 heteromer. The molecular bases of
binding of c-Ski to Smads in cells stimulated or not with
TGF- or BMP will be discussed.
MATERIALS AND METHODS
Cell Culture
COS-7 and HepG2 cells were maintained in DMEM (Sigma, St. Louis, MO)
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 g/ml
streptomycin. NMuMG cells were cultured in DMEM (Sigma) containing 10%
FBS and 5 g/ml insulin. C2C12 cells were maintained in DMEM (GIBCO,
Rockville, MD) containing 20% FBS.
Plasmids and Ligands
The construction of plasmids containing c-Ski was described previously
(Akiyoshi et al., 1999). c-Ski (ARPG) was provided by Dr. Nomura. c-Ski
W274E and c-Ski S2/3 were constructed as described by Wu et al. (2002).
Other mutants of c-Ski were constructed by a PCR-based approach. To
increase levels of expression, inserts were subcloned into an expression vec-
tor, pcDEF3 (Goldman et al., 1996). All of the PCR products were sequenced.
For expression in Xenopus embryos, Flag-tagged human c-Ski and c-Ski
(ARPG)-coding sequences were subcloned into pCS2 vector using EcoRI
and XhoI restriction sites. An expression plasmid containing activin (pSP64T-
activin B) has been described (Cho et al., 1991). Recombinant TGF-3, BMP-6,
and BMP-7 were from R&D Systems (Minneapolis, MN).
Transfection, Immunoprecipitation, and Immunoblotting
COS-7 cells were transiently transfected using FuGENE6 (Boehringer Mann-
heim, Indianapolis, IN). Twenty-four hours after transfection, cells were lysed
with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100).
Immunoprecipitation and immunoblotting were performed as described
(Kawabata et al., 1998). Anti-Flag M2 (Sigma) and anti-Myc 9E10 (PharMin-
gen, San Diego, CA) were used for immunoprecipitation and immunoblotting
of tagged proteins. Anti–phospho-Smad3 (pSmad3) was described previously
(Ota et al., 2002).
Luciferase Assay
Reporter plasmids used were (CAGA)9-MLP-Luc (Dennler et al., 1998) and
3GC2-Lux (Ishida et al., 2000). HepG2 cells were transiently transfected with
an appropriate combination of reporter constructs, expression plasmids, and
pcDNA3. Smad5 was cotransfected when we used 3GC2-Lux. Total amounts
of transfected DNAs were the same in each experiment. Twenty-four hours
after transfection, cells were stimulated with ligands (TGF-, 2.5 ng/ml;
BMP-7, 500 ng/ml) and cultured for another 24 h. Cell lysates were then
prepared and luciferase activities in the lysates were measured by the Dual-
Luciferase Reporter System (Promega, Madison, WI). Renilla luciferase activ-
ity under the control of thymidine kinase promoter was used for normaliza-
tion. In some experiments, expression level of recombinant proteins in lysates
was determined by immunoblotting.
Construction of Recombinant Adenoviruses
Recombinant adenoviruses carrying LacZ, Smad6, and Smad7 cDNAs were
described previously (Fujii et al., 1999). cDNAs encoding Flag-tagged c-Ski or
c-Ski (ARPG) mutant were subcloned into the SwaI site of the pAxCAwt
cassette cosmid. Each cosmid carrying the expression unit and adenovirus
DNA-terminal protein complex were cotransfected into E1 transcomplemen-
tal cell line 293. The recombinant adenoviruses generated by homologous
recombination were isolated. High-titered stocks of recombinant viruses were
grown in 293 cells and purified by ViraPrep kit (Virapur, Carlsbad, CA)
according to the manufacturer’s instructions.
Assay for Alkaline Phosphatase Activity
C2C12 cells were seeded at a density of 4  105 cells/well on six-well plates.
The next day, cells were infected with adenoviruses carrying various cDNAs
at a m.o.i. of 100. Twenty-four hours after infection, C2C12 cells were stim-
ulated with BMP-6 (200 ng/ml) for 96 h in DMEM containing 0.5% FBS, with
a change of medium at 48 h after stimulation. Cells were then washed, and
cellular proteins were extracted with a lysis buffer (20 mM Tris-HCl, pH 7.5,
150 mM NaCl, and 1% Triton X-100). Alkaline phosphatase activity was
determined using p-nitrophenyl phosphate (Sigma) as a substrate (Asahina et
al., 1993). Protein concentration of extracts was determined by BCA protein
assay kit (Pierce, Rockford, IL) using bovine serum albumin as a standard.
Assay for Epithelial-to-Mesenchymal Transdifferentiation
NMuMG cells were seeded at a density of 2  105 cells/well on six-well
plates. The next day, cells were infected with adenoviruses carrying various
cDNAs at a m.o.i. of 300. Twenty-four hours later, cells were stimulated with
TGF-3 (5 ng/ml). Another 24 h later, cell morphology was observed under
microscopy.
Xenopus Embryo Manipulation and Microinjection
Embryo manipulations and microinjections were conducted as described
previously (Cho et al., 1991). RNAs were injected into the animal pole at the
four-cell stage or into the marginal zone of a ventral blastomere at the
four-cell stage. Capped synthetic RNA was generated by in vitro transcription
of linearized templates using a Megascript kit (Ambion, Austin, TX).
Reverse Transcription-Polymerase Chain Reaction
RNA was isolated from pooled animal caps (at least 15) and reverse tran-
scription-polymerase chain reaction (RT-PCR) analysis was performed as
described (Nakayama et al., 1998) using the following PCR conditions: 94°C
for 5 min, followed by a variable number of cycles at 94°C for 30 s, 55°C for
30 s, and 72°C for 2 min. Muscle actin, neural cell adhesion molecule (NCAM),
and histone H4 primers have been described previously (Nakayama et al.,
1998). PCR products were visualized on ethidium-bromide–stained agarose
gels.
RESULTS
c-Ski (ARPG) Inhibits TGF- Signaling But Does Not
Inhibit BMP Signaling in Mammalian Cells
Wang et al. (2000) reported that c-Ski inhibited BMP-induced
transactivation of 15 GCCG-Luc reporter and osteoblastic
differentiation of W20–17 cells as well as endogenous BMP
signaling in Xenopus embryos. We also observed inhibition
of BMP signaling by c-Ski, v-Ski, and SnoN using a BMP-
responsive reporter, 3GC2-Lux (unpublished data).
ARPG mutation of Ski proteins has been reported to mod-
ulate effects of c-Ski or v-Ski on target cells (Colmenares et
al., 1989; Nomura et al., 1999). We examined how c-Ski
(ARPG) affects TGF- signaling and BMP signaling using
luciferase reporter assays (Figure 1). Interestingly, c-Ski
(ARPG) suppressed TGF- signaling but not BMP signaling.
To confirm this selectivity, we next examined the effect of
c-Ski and c-Ski (ARPG) on cell responses induced by TGF-
and by BMP.
C2C12 cells are undifferentiated mesenchymal cells that
differentiate into osteoblastic cells in response to BMP treat-
ment (Katagiri et al., 1994). This process was shown to be
mainly dependent on the Smad-signaling pathway because
it was enhanced by transfection of Smad1 or Smad5 and
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inhibited by inhibitory Smads, i.e., Smad6 and Smad7 (Fujii
et al., 1999). We examined the effects of c-Ski and c-Ski
(ARPG) on BMP-induced osteoblastic differentiation. C2C12
cells were infected with adenoviruses carrying various cD-
NAs and treated with BMP-6 for 96 h. Osteoblast differen-
tiation of infected cells was monitored by induction of alka-
line phosphatase activity (Figure 2, top panel). LacZ-infected
cells and uninfected cells exhibited BMP-dependent increase
of alkaline phosphatase activity. c-Ski-infected cells as well
as Smad6- or Smad7-infected cells exhibited decreased alka-
line phosphatase activity, whereas c-Ski (ARPG)-infected
cells efficiently differentiated into osteoblasts. We confirmed
that the levels of expression of c-Ski and c-Ski (ARPG) were
comparable by immunoblotting analysis (Figure 2, bottom
panel) and concluded that c-Ski (ARPG) failed to inhibit
BMP signaling.
We next examined the effects of c-Ski proteins on TGF-–
induced epithelial-to-mesenchymal transdifferentiation
(EMT) of NMuMG mouse mammary epithelial cells. TGF-
treatment causes morphological transformation of cells from
cuboidal epithelial morphology to elongated spindle-like
fibroblastic morphology, accompanying reorganization of
actin cytoskelton and downregulation of E-cadherin (Miet-
tinen et al., 1994). Effects of adenovirally overexpressed pro-
teins were examined by microscopic observation of cell mor-
phology (Figure 3). Overexpression of LacZ did not affect
this process, but that of Smad7 inhibited it (Figure 3, B and
C). c-Ski as well as c-Ski (ARPG) inhibited TGF-–induced
morphological change of NMuMG cells (Figure 3, D and E).
These results demonstrated the selectivity of inhibition by
c-Ski (ARPG) in mammalian cells in culture.
c-Ski (ARPG) Inhibits Activin Signaling but Does Not
Inhibit Endogenous BMP Signaling in Xenopus Embryos
To further explore the selectivity of c-Ski (ARPG) action on
TGF- superfamily signaling, effects of c-Ski proteins on
endogenous BMP signaling were examined using Xenopus
embryos. Overexpression of c-Ski in Xenopus embryos has
been reported to induce secondary neural axis formation
(Amaravadi et al., 1997) through suppression of endogenous
BMP signaling (Wang et al., 2000). We thus used this system
to determine effects of c-Ski (ARPG) on BMP signaling (Fig-
ure 4A and Table 1).
Injection of 500 pg of RNA encoding c-Ski into ventral
blastomeres of four-cell Xenopus embryos caused secondary
dorsal axis formation and/or a hyperdorsalized phenotype
in which the trunk and tail were severely reduced or lost
(Figure 4A, left). In contrast, most of the embryos developed
normally when 500 pg of RNA encoding c-Ski (ARPG) or
-globin was injected (Figure 4A, middle and right). These
results suggested that c-Ski (ARPG) no longer inhibited BMP
signaling.
We further examined the effect of c-Ski (ARPG) using an
animal cap assay. RNA encoding c-Ski or c-Ski (ARPG) was
injected into the animal pole of four-cell Xenopus embryos.
Animal caps were excised at the blastula stage 8, cultured
until stage 23, and then harvested. RNAs were extracted,
and expression of mesodermal marker gene (muscle actin)
and neural marker gene (NCAM) was analyzed by RT-PCR
(Figure 4B). Injection of RNA encoding c-Ski induced
NCAM in animal caps without inducing muscle actin, indi-
cating that c-Ski caused neuralization through inhibition of
BMP signaling but not through induction of mesoderm
(Wang et al., 2000). c-Ski (ARPG) failed to induce NCAM
(Figure 4B), indicating that c-Ski (ARPG) does not inhibit
endogenous BMP signaling in animal caps.
Next, we examined effects of c-Ski and c-Ski (ARPG) on
activin signaling. Injection of RNA encoding activin caused
Figure 1. c-Ski (ARPG) selectively suppressed TGF- signaling.
Luciferase reporter assay was conducted using (CAGA)9-MLP-Luc
(A, top) and 3GC2-Lux (B, bottom). Cells were stimulated with
TGF- (2.5 ng/ml) (A) or BMP-7 (500 ng/ml) (B). , unstimulated
samples; f, ligand-stimulated samples. Expression of recombinant
proteins was determined by immunoblotting analysis of the cell
lysates using anti-Flag M2 antibody (bottom).
Figure 2. c-Ski (ARPG) failed to inhibit BMP-induced osteoblastic
differentiation of C2C12 cells. C2C12 cells were infected with ad-
enoviruses carrying various cDNAs, followed by BMP-6 treatment
(200 ng/ml) for 96 h. Osteoblastic differentiation was monitored by
induction of alkaline phosphatase activity (top). , unstimulated
samples; f, BMP-6–stimulated samples. Expression of recombinant
proteins was determined by immunoblotting analysis of the cell
lysates using anti-Flag M2 antibody (bottom).
c-Ski Inhibition of TGF-/BMP Signaling
Vol. 15, March 2004 965
mesodermal induction in animal caps, resulting in expres-
sion of muscle actin (Figure 4C). Coinjection of c-Ski or c-Ski
(ARPG) inhibited activin-induced expression of muscle ac-
tin, indicating that both c-Ski and c-Ski (ARPG) inhibited
activin signaling. These results indicated that c-Ski (ARPG)
inhibits activin signaling but does not inhibit BMP signaling
in Xenopus embryos.
c-Ski (ARPG) Recruits HDAC1 to Smad3-Smad4 Complex,
But Not to Smad5-Smad4 or to Smad1-Smad4 Complex
We next addressed the question how c-Ski (ARPG) selec-
tively inhibits TGF-/activin signaling. We first examined
effects of the ARPG mutation on recruitment of HDAC1 to
activated Smad complexes. It is established that Smad2/3-
Smad4 complex mediates TGF-/activin signaling, whereas
Smad1/5-Smad4 complex mediates BMP signaling. Smad3,
Smad5, or Smad1 was coexpressed in COS-7 cells with
Smad4, c-Ski, mSin3A, HDAC1, and constitutively active
form of TGF- type I receptor (ALK-5) or BMP type IB
receptor (ALK-6), followed by immunoprecipitation of
Smad proteins. Coprecipitated proteins were visualized by
immunoblotting (Figure 5A). HDAC1 was recruited to
Smad3-Smad4 complex in the presence of c-Ski as well as
c-Ski (ARPG), although c-Ski recruited more HDAC1 than
did c-Ski (ARPG). However, HDAC1 was recruited to
Smad5-Smad4 complex or Smad1-Smad4 complex only in
the presence of wild-type c-Ski. This result explains selec-
tivity for TGF-/activin signaling in suppression by c-Ski
(ARPG). Notably, c-Ski (ARPG) itself was not coprecipitated
with Smad5-Smad4 complex nor Smad1-Smad4 complex. To
explore this further, we examined the interaction of c-Ski
(ARPG) with each of the Smad proteins.
Lack of Smad4 Binding Confers TGF-/Activin Selectivity
to c-Ski (ARPG)
Smad3, Smad4, Smad5, or Smad1 was coexpressed in COS-7
cells with c-Ski and constitutively active type I receptors
(ALKs), followed by immunoprecipitation of c-Ski and im-
munoblotting (Figure 5B). Smad3 was coprecipitated with
c-Ski and with c-Ski (ARPG). In contrast, Smad4 was copre-
cipitated with c-Ski but only weakly with c-Ski (ARPG).
Smad5 and Smad1 were coprecipitated with neither c-Ski
nor c-Ski (ARPG) in the present experimental conditions.
These results strongly suggested that lack of Smad4 binding
confers the selectivity of inhibition to c-Ski (ARPG).
Because c-Ski (ARPG) lacks the ability to bind Smad4, it
appeared likely that suppression of TGF- signaling by c-Ski
(ARPG) principally depends on its interaction with R-Smad.
We therefore examined the effect of a mutation to abolish
R-Smad binding on c-Ski (ARPG). The R-Smad binding re-
gion has recently been reported to be located between amino
acid residues 16 and 40 (Qin et al., 2002) or the N-terminal 23
amino acid residues (Wu et al., 2002) of c-Ski. Although
Smad2/3 also binds the middle region of c-Ski (amino acid
residues 335–490 or 241–441), the affinity of the middle
region appears to be lower than that of the N-terminal
region (Akiyoshi et al., 1999; He et al., 2003; our unpublished
observation). We thus constructed a truncated mutant lack-
ing the N-terminal 40 amino acid residues (40) as well as a
double mutant with 40 and ARPG insertion and confirmed
that the 40 mutation caused loss of R-Smad binding. As
shown in Figure 5C, c-Ski (ARPG) as well as c-Ski (40)
inhibited TGF-–induced transactivation of (CAGA)9-MLP-
Luc, whereas the ARPG-40 double mutant lost a significant
amount of inhibitory activity. These results indicate that
inhibition of TGF- signaling by ARPG mutant is principally
dependent on its interaction with Smad2/3.
To confirm that loss of inhibition of BMP signaling is due
to lack of Smad4 binding, we used c-Ski W274E mutant,
which was recently reported to lack Smad4 binding (Wu et
al., 2002). We confirmed that the mutant binds to Smad3 but
not to Smad4. c-Ski W274E inhibited TGF-–induced trans-
activation of (CAGA)9-MLP-Luc reporter construct (Figure
6A, left), consistent with the finding obtained by Wu et al.
(2002), who used AR3-Lux and constitutively active ALK-4.
We also examined the effect of the W274E mutant on BMP-
induced trans-activation of 3GC2-Lux and found that the
W274E mutant did not inhibit trans-activation (Figure 6A,
right). The W274E mutant recruited HDAC1 to Smad3-
Smad4 complex but not to Smad5-Smad4 complex, entirely
Figure 3. Inhibition of TGF-–induced EMT in NMuMG cells by
c-Ski and c-Ski (ARPG). NMuMG cells were infected with adenovi-
ruses carrying various cDNAs, followed by TGF- treatment (5
ng/ml). Twenty-four hours after ligand stimulation, cell morphol-
ogy was observed under microscopy. Control cells (left panels) and
TGF-–treated cells (right panels) are shown for noninfected cells
(A) and cells infected with adenoviruses carrying LacZ (B), Smad7
(C), c-Ski (D), and c-Ski (ARPG) (E).
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consistent with the result obtained using c-Ski (ARPG) (Fig-
ure 6B).
On the basis of results obtained with two different types of
mutants lacking Smad4 binding, we concluded that lack of
Smad4 binding in c-Ski results in selective loss of inhibition
of BMP signaling.
Effect of c-Ski on Complex Formation between R-Smads
and Co-Smads
Wu et al. (2002) recently proposed a novel model of c-Ski–
mediated inhibition of Smad signaling: c-Ski binding causes
disruption of oligomerization of R-Smads and Co-Smads,
thus abrogating Smad function. We then examined how lack
of Co-Smad or R-Smad binding in c-Ski affects the complex
formation of R-Smads, Co-Smad, and c-Ski. We performed
complex formation assays, in which differently tagged c-Ski,
Smad3, and/or Smad4 were coexpressed and stimulated
with constitutively active ALK-5, followed by immunopre-
cipitation of c-Ski or Smad proteins and visualization of
coprecipitated proteins by immunoblotting.
First, we used c-Ski W274E, which was reported to lack
Smad4 binding (Figure 7, A and B). In Figure 7A, c-Ski
W274E was immunoprecipitated and coprecipitated pro-
teins were analyzed. When c-Ski W274E was coexpressed
with Smad3, Smad3 was coprecipitated with c-Ski W274E in
a signal-dependent manner. When c-Ski W274E was coex-
pressed with Smad4, Smad4 was only very weakly copre-
cipitated with c-Ski W274E irrespective of the input of
TGF- signaling. When coexpressed both with Smad3 and
Smad4, c-Ski W274E coprecipitated not only Smad3 but also
Smad4 even in the absence of TGF- signaling. Because c-Ski
W274E does not efficiently interact with Smad4, coprecipi-
tation of Smad4 is most likely mediated through Smad3,
suggesting that c-Ski W274E interacted with Smad3-Smad4
heteromer. In Figure 7B, Smad4 was immunoprecipitated to
examine c-Ski-Smad complexes. Smad4 only weakly inter-
acted with c-Ski W274E, but interacted with Smad3 in a
signal-dependent manner. Notably, c-Ski W274E was copre-
cipitated with Smad4 in the presence of Smad3. Again, c-Ski
W274E was shown to interact with Smad3-Smad4 hetero-
mer. We obtained essentially the same results when we used
c-Ski (ARPG) instead of c-Ski W274E (Figure 7C and unpub-
lished data). We thus concluded that disruption of R-Smad-
Co-Smad heteromer is not the sole mechanism of inhibition
of TGF-/activin signaling by c-Ski (ARPG) or c-Ski W274E.
Next, we used c-Ski S2/3, which does not interact with
R-Smads (Wu et al., 2002). Smad3 and c-Ski S2/3 were
coexpressed and c-Ski S2/3 was immunoprecipitated (Fig-
ure 7D). Smad3 was not coprecipitated in the absence of
Smad4, whereas it was coprecipitated in a signal-dependent
manner in the presence of Smad4. These results indicate that
c-Ski S2/3 interacts with Smad3-Smad4 heteromer.
We also noticed that c-Ski W274E interacted with Smad3-
Smad4 heteromer in a signal-independent manner, whereas
c-Ski S2/3 interacted with Smad3-Smad4 heteromer in a
signal-dependent manner. To elucidate whether this signal-
independent interaction with Smad3 is a unique feature of
W274E mutant, we examined complex formation using
Figure 4. Effects of c-Ski (ARPG) on signal-
ing of TGF- superfamily in Xenopus em-
bryos. (A) Effect on endogenous BMP signal-
ing using whole embryos. Equivalent
amounts (500 pg) of RNAs encoding c-Ski,
c-Ski (ARPG), or -globin were injected near
the ventral midline of four-cell Xenopus em-
bryos. Resultant phenotypes in a representa-
tive experiment are shown (left, c-Ski; middle,
c-Ski (ARPG); and right, -globin). (B) Effect
on endogenous BMP signaling in animal caps.
RNA encoding c-Ski or c-Ski (ARPG) was in-
jected into the animal pole of four-cell em-
bryos. Animal caps were excised at brastulla
stage 8 and cultured until stage 23. RNAs
were then extracted from the animal caps and
expression of marker genes (muscle actin and
NCAM) was analyzed by RT-PCR. Histone
H4 was used as a loading control. (C) Effect
on activin signaling in animal caps. RNA en-
coding c-Ski or c-Ski (ARPG) was injected
together with RNA encoding activin into the
animal pole of four-cell embryos, and expres-
sion of marker genes was analyzed as de-
scribed above.
Table 1. Dorsalizing activity of c-Ski and c-Ski (ARPG) in whole
Xenopus embryos
Injected RNA (pg) Dorsalized phenotypes (%)
c-Ski
c-Ski
(ARPG) -globin
Secondary
axis Hyperdorsalized Total N
0 0 0 0 0 0 41
0 0 500 5 0 5 20
500 0 0 69 28 97 36
250 0 0 88 3 91 40
125 0 0 50 29 79 34
0 500 0 21 0 21 38
0 250 0 5 0 5 44
0 125 0 7 0 7 15
RNA encoding -globin, c-Ski, or c-Ski (ARPG) was injected near
the ventral midline of four-cell Xenopus embryos. The total number
of uninjected or injected embryos surviving to tadpole stage (N) and
the percentage of these embryos exhibiting either a secondary dor-
sal axis or hyperdorsalization with no apparent secondary axis are
indicated. Data are pooled from multiple experiments.
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wild-type c-Ski (Figure 7E). Wild-type c-Ski interacted with
Smad3 in a signal-dependent manner, but with Smad4 in a
signal-independent manner. When coexpressed with both
Smad3 and Smad4, c-Ski interacted with Smad3 even in the
absence of signaling. We confirmed that Smad3 bound to
Smad4 and c-Ski in the absence of TGF- signaling is un-
phosphorylated. Taken together with the results obtained
using c-Ski mutants, these findings suggest that c-Ski and
Smad4 cooperate in stabilizing complexes composed of c-Ski
and Smad3-Smad4 heteromer (see DISCUSSION).
The results presented here have raised the possibility that
c-Ski mutants lacking Smad4 binding does not interfere with
R-Smad-Co-Smad interaction. To address this issue directly,
we examined the effects of c-Ski and c-Ski mutants on
Smad3-Smad4 heteromer formation (Figure 7F). Flag-tagged
Smad3 and 6Myc-tagged Smad4 were expressed in COS
cells, followed by immunoprecipitation of Smad4. In the
absence of c-Ski, Smad3 was coimmunoprecipitated in a
signaling-dependent manner. We then examined how in-
creasing levels of c-Ski affect the coprecipitation. When wild-
type c-Ski was coexpressed, c-Ski as well as Smad3 was
coprecipitated with Smad4; the amount of coprecipitated
Smad3 was not decreased. To exclude the possibility of
bridging effect of wild-type c-Ski that interacts both with
Smad3 and Smad4, we next used c-Ski (ARPG) and c-Ski
W274E that do not interact with Smad4. Coexpression of
c-Ski mutants did not cause reduction of coprecipitated
Smad3, indicating that heteromer formation between Smad3
and Smad4 was not abrogated by c-Ski proteins. c-Ski mu-
tants were also coprecipitated upon immunoprecipitation of
Smad4, confirming the interaction of c-Ski mutants with
Smad3. We thus concluded that c-Ski mutants, c-Ski (ARPG)
Figure 5. Interaction of c-Ski (ARPG) with Smad
proteins. (A) Recruitment of HDAC1 to activated
Smad complexes by c-Ski and c-Ski (ARPG) and
(B) binding of c-Ski and c-Ski (ARPG) to each of
the Smad proteins. COS-7 cells were transfected
with indicated plasmids. Smad proteins (A) or
c-Ski (B) was immunoprecipitated from cell ly-
sates and coprecipitated proteins were visualized
by immunoblotting. ALK-5TD and ALK-6QD are
constitutively active forms of ALK-5 and ALK-6,
respectively. (C) c-Ski (ARPG) suppression of
TGF- signaling was dependent on R-Smad bind-
ing. c-Ski (40) lacks the N-terminal 40 amino acid
residues and therefore cannot bind Smad2/3. c-
Ski (ARPG40) is a double mutant of (ARPG) and
(40). Luciferase reporter assay was conducted in
HepG2 cells stimulated with TGF- (2.5 ng/ml)
using (CAGA)9-MLP-Luc. , unstimulated sam-
ples; f, TGF-–stimulated samples.
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and c-Ski W274E, suppress TGF- signaling without dis-
rupting Smad heteromer formation.
DISCUSSION
Interaction with Smad4 Is Essential for Suppression of
BMP Signaling by c-Ski
The ARPG mutant of Ski protein, in which four amino acids
(Ala-Arg-Pro-Gly) are inserted in a potential amphipathic
region, has been reported to cause altered cellular responses
in mammalian cells (Colmenares and Stavnezer, 1989; Col-
menares et al., 1991; Nomura et al., 1999). In the present
study, we established that c-Ski (ARPG) selectively inhibits
TGF-/activin signaling using various assay systems.
We further found that c-Ski (ARPG) recruits HDAC1 to
the Smad3-Smad4 complex but not the Smad5-Smad4 com-
plex, a finding attributed to lack of Smad4 binding in this
mutant. Recently, the crystal structure of c-Ski (219–312)-
Smad4 MH2 domain was determined and detailed informa-
tion on the c-Ski-Smad4 binding surface was reported (Wu et
al., 2002). The L3 loop of Smad4 interacts with a loop struc-
ture in c-Ski termed the I-loop that is well conserved among
c-Ski and SnoN of various species. Because the I-loop spans
amino acid residues 259–281, it is distantly located from the
ARPG mutation site, which is located around residue 181.
Wang et al. (2000) previously reported that amino acid res-
idues 222 and 223 are important in binding to Smad4. These
residues have subsequently been shown to support the I-
loop structure, although they are not directly involved in the
interaction with Smad4 (Wu et al., 2002). Thus, ARPG inser-
tion may also affect Smad4 binding in a similar manner.
Using a point mutant, c-Ski W274E (Wu et al., 2002) as well
as c-Ski (ARPG), we found that lack of Smad4 binding is a
key event in exhibiting selectivity of inhibition of TGF-/
activin signaling. Although Smad1 and Smad5 have been
reported to interact with c-Ski (Wang et al., 2000), we did not
detect the interaction in our hands (Figure 5B). Smad4 bind-
ing appears to be essential for c-Ski–mediated suppression
of BMP signaling. This property is strikingly different from
that of TGF- signaling; loss of interaction with Smad4 does
not lead to loss of inhibition of TGF- signaling. The inhi-
bition of TGF-/activin signaling by c-Ski (ARPG) was de-
pendent on its interaction with Smad2/3. The mode of in-
hibition of TGF-/activin signaling and BMP signaling by
c-Ski and c-Ski (ARPG) is summarized in Figure 8, A and B.
Mode of Binding of c-Ski to Smad2/3
Wu et al. (2002) suggested that binding of c-Ski to R-Smad or
Co-Smad causes disruption of active Smad complexes. Be-
cause wild-type c-Ski can interact with Smad2/3 and Smad4
simultaneously, it would be difficult to directly demonstrate
that Smad2/3-Smad4 heteromer is actually disrupted; only
an approach using mutant proteins would be available for
this purpose.
In the present study, we demonstrated that c-Ski mutants
lacking Smad4 binding, c-Ski (ARPG) and c-Ski W274E,
interact with Smad3 but do not disrupt Smad3-Smad4 het-
eromers. This result is consistent with our previous obser-
vation that c-Ski interacts with Smad2/3 through the upper
surface of the MH2 toroid structure of Smad2/3 trimer
(Mizuide et al., 2003). We further examined how c-Ski affects
Smad heteromeric complex using c-Ski S2/3, which inter-
acts with Smad4 but not with R-Smads. We detected copre-
cipitation of c-Ski S2/3 with Smad3-Smad4 heteromer.
These results raise the possibility that wild-type c-Ski can
also interact with Smad proteins without abrogating forma-
tion of active Smad complexes.
We also observed that c-Ski W274E induced formation of
Smad3-Smad4 complexes even in the absence of signaling.
Correia et al. (2001) reported that Smad3 tends to trimerize
and that this tendency is dramatically enhanced by C-termi-
nal phosphorylation of Smad3. Qin et al. (2002) found that
the N-terminal region of c-Ski (residues 16–40) preferen-
tially interacts with a Smad3 conformer that favors oli-
gomerization. Interaction of c-Ski with Smad3 may stabilize
the Smad3 conformer for oligomerization even in unphos-
phorylated form, which may be further stabilized by the
presence of Smad4 through formation of Smad3-Smad4 het-
eromer. The stabilizing effect of Smad4 on unphosphory-
lated Smad3-c-Ski complex was also observed when we
used wild-type c-Ski.
Recently, Prunier et al. (2003) reported that c-Ski in-
duces Smad2/3-Smad4 heteromeric complex formation
independent of TGF- signaling. They concluded that
c-Ski-Smad4 interaction is required for induction of
Smad2/3-Smad4 complex formation based on results ob-
tained using c-Ski del A, an N-terminally truncated mu-
tant of c-Ski, which spans amino acid residues 335–728
Figure 6. Selective loss of suppression of BMP signaling by c-Ski
W274E mutant. (A) Luciferase reporter assay in HepG2 cells stim-
ulated with TGF- or BMP-7 using (CAGA)9-MLP-Luc (left) and
3GC2-Lux (right), respectively., unstimulated samples; f, ligand-
stimulated samples. (B) Recruitment of HDAC1 to activated Smad
complexes. COS-7 cells were transfected with indicated plasmids.
Smad proteins were immunoprecipitated from cell lysates and co-
precipitated proteins (c-Ski and HDAC1) were visualized by immu-
noblotting. ALK-5TD and ALK-6QD are constitutively active forms
of ALK-5 and ALK-6, respectively.
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(Akiyoshi et al., 1999). c-Ski del A lacks a Smad4 binding
region as well as an N-terminal R-Smad binding region
that has been reported to preferentially interact with the
trimeric conformer of Smad3. However, c-Ski del A can
weakly interact with Smad2/3 through its middle region
(Akiyoshi et al., 1999). In the present study, we observed
that Smad3-Smad4 heteromer formation was promoted by
c-Ski W274E, which lacks interaction with Smad4, but was
not promoted by c-Ski S2/3, which lacks interaction
with Smad2/3. The failure of c-Ski del A to induce signal-
independent Smad3-Smad4 heteromer formation can be
attributed to the lack of N-terminal R-Smad binding re-
gion but not to the lack of Smad4 binding.
Molecular Basis for the Loss of Transforming Activity of
v-Ski (ARPG) Mutant
The ARPG mutation of Ski protein was first described as a
transformation-defective mutation in v-Ski (Colmenares et al.,
1991). Although the oncogenic mechanism of v-Ski is not fully
understood, suppression of TGF-–induced growth inhibition
is thought to be a part of the oncogenic properties of Ski
proteins (He et al., 2003). v-Ski has a truncated structure in both
the N- and C- termini of c-Ski; v-Ski lacks a 23-amino acid
region from its N-terminus, and a 292-amino acid region from
its C-terminus (Stavnezer et al., 1989). Because the truncated
region in the N-terminus constitutes the R-Smad binding site,
v-Ski is unable to interact with R-Smads (He et al., 2003). The
Figure 7. Effects of c-Ski proteins on complex formation of Smad proteins. COS-7 cells were transfected with various combination of cDNAs
(Smad3, Smad4, c-Ski, and ALK-5TD). c-Ski (wild-type or mutant) or Smad4 was immunoprecipitated and coprecipitated proteins were
visualized by immunoblotting. Effect of c-Ski W274E on complex formation was examined by immunoprecipitating c-Ski W274E (A) or
Smad4 (B). Effect of c-Ski (ARPG) (C), c-Ski S2/3 (D), or wild-type c-Ski (E) was examined by immunoprecipitating c-Ski proteins. Effects
of increasing amounts of c-Ski proteins on heteromer formation were also examined by immunoprecipitating Smad4 (F).
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C-terminal truncated region includes one of the mSin3A bind-
ing regions (Nomura et al., 1999). Because the ARPG mutation
was reported to cause loss of NCoR binding, v-Ski (ARPG) is
thought to lack these two repressor regions, although presence
of another repressor domain has been suggested (Nomura et
al., 1999). We recently identified a novel mSin3A-dependent
repressor region spanning amino acid residues 150–240 and
found that this region is not affected by ARPG mutation (our
unpublished observation). Thus, loss of transforming activity
of v-Ski (ARPG) may not be due to the loss of HDAC recruit-
ment. Remarkably, we found that ARPG insertion caused loss
of Smad4 binding ability, suggesting that v-Ski (ARPG) would
be unable to interact with both R-Smads and Co-Smad. This
property can thus explain in part the loss of transforming
activity in v-Ski (ARPG) mutant (Figure 8, C and D).
EMT Is a Smad-dependent Process
EMT by TGF- is now regarded as one of the key events
during tumor progression (Piek and Roberts, 2001), but the
mechanism of this process is not fully understood. Piek et al.
(1999) reconstituted components of TGF- signaling in
NMuMG cells by adenovirus infection and found that con-
stitutively-active ALK-5 triggered EMT only when it was
coexpressed with Smad2 and Smad4, or with Smad3 and
Smad4. Oft et al. (2002) reported that the constitutively active
form of Smad2 cooperates with activated H-Ras to induce
EMT. These reports suggest that EMT is a Smad-dependent
process. In contrast, Bhowmick et al. (2001) reported that
expression of Smad7 or dominant-negative Smad3 did not
inhibit EMT and proposed that the RhoA-dependent path-
way plays an indispensable role in EMT. A role of phospha-
tidylinositol 3-kinase in EMT has also been reported (Bakin
et al., 2000). In the present study, we observed that overex-
pression of Smad7 as well as that c-Ski inhibited EMT.
Because c-Ski specifically targets Smad signaling at the level
of transcription, our results strongly suggest that TGF-–
induced EMT is dependent on Smad-mediated transcrip-
tion. However, they do not exclude contribution by other
pathways. Further studies are thus required to elucidate the
mechanism of EMT in detail.
Use of c-Ski (ARPG) as an Antagonist of TGF-/Activin
Signaling Targeting Smad-dependent Transcriptional
Activation
Because overactivity of TGF- signaling is implicated in
many pathological processes, development of useful antag-
onists of TGF- signaling is highly desired. Successful use of
various types of TGF- antagonists has been reported in
mouse pathological models. Recombinant soluble Fc-TGF-
type II receptor fusion protein was used to suppress breast
cancer metastasis (Muraoka et al., 2002; Yang et al., 2002).
Adenoviruses carrying cDNA encoding Smad7 were used to
prevent pulmonary fibrosis induced by bleomycin adminis-
tration (Nakao et al., 1999), although Smad7 also blocks BMP
signaling. Recently, a low-molecular-weight synthetic com-
pound, SB-431542, which selectively inhibits ALK-4/5/7 ki-
nase but not ALK-1/2/3/6 kinase, was developed (Inman et
al., 2002), although its effects in vivo have not yet been
examined. Considering the multifunctional properties of
TGF-, however, pathway-specific antagonists would be
more favorable for clinical applications (Akhurst, 2002). One
unique feature of c-Ski (ARPG) is that it selectively sup-
presses TGF-/activin signaling at the level of transcription
and thus is not supposed to inhibit Smad-independent sig-
naling. In the present study, we demonstrated the selective
action of c-Ski (ARPG) in vivo using Xenopus embryo sys-
tem; c-Ski (ARPG) did not inhibit endogenous BMP signal-
ing in whole embryos as well as in animal caps, whereas it
inhibited activin signaling in animal caps. It would be inter-
esting to explore effects of this unique mutant on other
cellular responses to TGF- and activin.
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